Antares Pharma Regains NYSE Amex Listing Compliance

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has received a letter from the NYSE Amex informing the Company that it has now resolved matters relating to its exchange listing compliance.

In the communication from NYSE Amex, the exchange indicated that based upon a review of publicly available information including its Securities and Exchange Commission filings, Antares has resolved the continued listing deficiency referenced in the NYSE Amex letter dated June 1, 2009.

About Antares Pharma (www.antarespharma.com)

Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems.Antares has multiple development partnerships with leading pharmaceutical companies. The Company’s products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares has three validated drug delivery systems: the ATDTM Advanced Transdermal Gel Delivery system, injection technology platforms including both VibexTM disposable pressure assisted auto injectors and Vision® reusable needle-free injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. Antares Pharma leverages its multiple drug delivery systems to add value to existing drugs and to create new products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Contacts:

Antares Pharma
Robert F. Apple, 609-359-3020
Executive Vice President and Chief Financial Officer
or
In-Site Communications, Inc.
Lisa Wilson, 917-543-9932
President
lwilson@insitecony.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.